Autoimmune Diseases Statistics in US 2026 | Key Facts

Autoimmune Diseases in the US 2026

Autoimmune diseases represent one of the most significant and rapidly growing health crises in the United States, affecting millions of Americans across all demographic groups. These conditions occur when the immune system mistakenly attacks the body’s own healthy tissues and organs, resulting in chronic inflammation and damage to multiple organ systems. According to groundbreaking research published in the Journal of Clinical Investigation in December 2024, over 15.4 million Americans—representing 4.6% of the US population—have been diagnosed with at least one of 105 autoimmune diseases between January 2011 and June 2022. This first-of-its-kind nationwide prevalence study, conducted by Mayo Clinic researchers using electronic health records from over 10 million patients across six large medical systems, provides the most comprehensive assessment of autoimmune disease burden in the US 2026 to date.

The epidemiological trends surrounding autoimmune diseases reveal alarming patterns that demand urgent public health attention. Autoimmunity itself appears to be rising dramatically, with the prevalence of antinuclear antibodies (ANA)—the most common biomarker of autoimmune activity—increasing from 11.0% in 1988-1991 to 15.9% in 2011-2012, representing an estimated 41 million affected individuals by 2012. Among adolescents aged 12-19 years, ANA prevalence increased nearly 300% over the same period, a particularly concerning trend given that autoimmune diseases typically manifest in young adulthood. Females comprise 63% of those diagnosed with autoimmune diseases, experiencing rates nearly twice as high as males, while 34% of patients are diagnosed with multiple coexisting autoimmune conditions. The worldwide incidence and prevalence of autoimmune diseases are increasing at estimated rates of 19.1% and 12.5% per year respectively, with individual conditions showing even more dramatic rises: type 1 diabetes prevalence has nearly doubled in 40 years, celiac disease has increased five-fold in 30 years, and multiple sclerosis cases worldwide increased 30% between 2013-2022. These autoimmune disease statistics in US 2026 underscore an urgent need for enhanced research funding, improved diagnostic tools, equitable healthcare access, and comprehensive prevention strategies.

Key Interesting Facts About Autoimmune Diseases in the US 2026

Data Sources: Journal of Clinical Investigation December 2024, National Institutes of Health 2020, CDC National Center for Health Statistics 2025, Mayo Clinic Autoimmune Study 2024, National Health Council 2025, Lupus Foundation of America 2025

The facts presented above illustrate the staggering scope of the autoimmune disease crisis in the US 2026. With over 15.4 million Americans diagnosed with at least one autoimmune disease, this category of conditions affects more individuals than many other widely recognized chronic disease categories. The 4.6% prevalence rate means that approximately 1 in 22 Americans lives with an autoimmune disease, though this figure likely underestimates the true burden as many conditions remain undiagnosed or misdiagnosed for years. The identification of 105 distinct autoimmune diseases in the Mayo Clinic study represents the most comprehensive categorization to date, ranging from common conditions affecting millions (such as rheumatoid arthritis with 10.6 million cases and type 1 diabetes with 2 million cases) to rare disorders affecting only thousands.

The gender disparity is one of the most striking features of autoimmune diseases in the US 2026, with females representing 63% of all diagnosed cases and experiencing rates nearly twice as high as males. This pattern varies considerably across specific conditions, with some diseases like lupus and Sjögren’s disease affecting women at rates 9-10 times higher than men, while others like type 1 diabetes affect both sexes relatively equally. The finding that 34% of patients have multiple coexisting autoimmune diseases highlights the interconnected nature of these conditions and suggests shared genetic and environmental risk factors. Most alarming is the temporal trend data showing that ANA prevalence increased from 11.0% to 15.9% over approximately 20 years, with adolescents experiencing a 300% increase—suggesting that younger generations face unprecedented risk for developing autoimmune diseases. The worldwide increases in individual conditions—type 1 diabetes nearly doubling, celiac disease increasing five-fold, and multiple sclerosis cases rising 30%—demonstrate that this is not merely improved detection but represents genuine increases in disease occurrence requiring urgent public health response.

Overall Prevalence of Autoimmune Diseases in the US 2026

Data Source: Journal of Clinical Investigation Mayo Clinic Study December 2024, National Center for Health Statistics 2025

The overall prevalence of autoimmune diseases in the US 2026 encompasses 15.4 million Americans, representing 4.6% of the total US population of approximately 333 million. This comprehensive estimate, derived from electronic health record data across six major medical systems serving over 10 million patients, represents the first nationwide assessment using consistent methodology for 105 different autoimmune diseases. The calculation required patients to have at least two diagnosis codes for the same autoimmune condition separated by at least 30 days, minimizing the inclusion of false-positive diagnoses while potentially underestimating prevalence by excluding individuals who were diagnosed but did not seek follow-up care or who were misdiagnosed.

The gender disparity is substantial, with females comprising 63% (approximately 9.7 million) and males 37% (approximately 5.7 million) of affected individuals. This translates to an estimated 5.8% of females and 3.4% of males living with at least one autoimmune disease, making women nearly twice as likely to be diagnosed. Age-related patterns show increasing prevalence with advancing age, from approximately 3.2% among adults aged 20-44 to 7.8% among those 65 and older, though many autoimmune diseases have peak onset during reproductive years (ages 20-50) in women. A critical finding is that 34% of individuals diagnosed with one autoimmune disease develop at least one additional autoimmune condition—approximately 5.2 million Americans—reflecting shared genetic susceptibilities and immune dysregulation mechanisms. The autoimmune disease statistics in the US 2026 demonstrate that while these conditions have historically been studied individually, they must increasingly be understood as interconnected manifestations of systemic immune dysfunction requiring coordinated, multidisciplinary healthcare approaches.

Top Autoimmune Diseases by Prevalence in the US 2026

Data Source: Mayo Clinic Journal of Clinical Investigation Study 2024, CDC NHANES 2017-2025, Various Disease-Specific Registries 2024-2025

The top autoimmune diseases by prevalence reveal both the diversity and commonality of these conditions across the US 2026 population. Rheumatoid arthritis stands as the single most prevalent autoimmune disease with an estimated 10.6 million Americans affected (15.8% of those with any autoimmune condition), based on CDC NHANES data from 2017-2020 that found 15.8% of adults with diagnosed arthritis specifically reporting rheumatoid arthritis. This chronic inflammatory condition primarily affects the joints but can involve multiple organ systems, with women experiencing rates approximately three times higher than men. Psoriasis, affecting 7.5 million Americans, represents the second most common condition, though its classification as purely autoimmune versus autoinflammatory remains debated.

Type 1 diabetes affects approximately 2 million Americans, including 304,000 children and adolescents, making it the most common autoimmune disease in pediatric populations. Unlike most autoimmune diseases, type 1 diabetes affects males slightly more than females in some age groups. Thyroid autoimmunity is extraordinarily common, with thyroid autoantibodies present in approximately 18% of US adults (20 million people), including 25% of older persons, though not all develop clinical autoimmune thyroiditis (Hashimoto’s thyroiditis). Graves’ disease and Hashimoto’s thyroiditis combined affect over 21 million Americans, with females experiencing rates 5-10 times higher than males. Systemic lupus erythematosus (SLE), while affecting 1.5 million Americans, carries particularly severe morbidity and mortality, especially among racial and ethnic minorities. The autoimmune disease statistics in the US 2026 demonstrate that while individual conditions vary in prevalence from relatively common (affecting millions) to rare (affecting thousands), their collective impact touches nearly one in 22 Americans, with most conditions disproportionately affecting women during their most productive years.

Gender Disparities in Autoimmune Diseases in the US 2026

Data Source: Mayo Clinic Study 2024, NIH Office of Autoimmune Disease Research 2025, Various Disease-Specific Registries 2024-2025

The gender disparity in autoimmune diseases in the US 2026 represents one of the most pronounced sex-based differences in medicine, with females comprising 63% of all diagnosed cases and males 37%. However, this overall ratio masks extraordinary variation across specific conditions. Sjögren’s syndrome and systemic lupus erythematosus demonstrate the most extreme female predominance at 9:1 ratios, meaning that 9 out of 10 patients are women. Autoimmune thyroid diseases (Hashimoto’s thyroiditis and Graves’ disease) affect women at 8-10 times and 5-10 times the rate of men respectively, contributing substantially to the overall female predominance given these conditions’ high prevalence. Rheumatoid arthritis shows a 3:1 female:male ratio, while multiple sclerosis affects women approximately 2-3 times more frequently than men.

Notably, not all autoimmune diseases show female predominance. Type 1 diabetes affects males and females relatively equally, though some studies show slightly higher rates in males at certain ages. Psoriasis likewise affects both sexes at approximately equal rates. The reasons underlying these dramatic gender differences remain incompletely understood but likely involve complex interactions between sex hormones (particularly estrogen), X chromosome effects, and differences in immune system function between sexes. Women tend to mount more robust immune responses than men, which provides advantages in fighting infections but increases vulnerability to autoimmune conditions. Many women report symptom worsening during particular phases of their menstrual cycles, during pregnancy, or in the postpartum period, strongly implicating hormonal influences. The autoimmune disease statistics in the US 2026 demonstrate that these conditions disproportionately impact women during their most productive years (ages 20-50), affecting employment, family planning, and quality of life at critical life stages, yet research funding and clinical attention have historically not reflected this disproportionate burden on women’s health.

Rising Trends in Autoimmunity in the US 2026

Data Source: NIH/NIEHS ANA Study 2020, National Health Council 2025, Various Disease Registries 2024-2025

The temporal trends in autoimmunity and autoimmune diseases in the US 2026 reveal alarming increases that cannot be explained by improved detection alone. The most comprehensive evidence comes from National Health and Nutrition Examination Survey (NHANES) data analyzing antinuclear antibody (ANA) prevalence—the most common autoimmune biomarker—across three time periods. ANA prevalence increased from 11.0% in 1988-1991 to 11.5% in 1999-2004 to 15.9% in 2011-2012, representing 45% relative increase over approximately 20 years. This translates to an estimated 22 million affected individuals in 1988-1991, 27 million in 1999-2004, and 41 million by 2011-2012—an additional 19 million Americans developing autoimmune markers over two decades.

The most concerning aspect of these trends is the disproportionate increases among specific demographic groups. Adolescents aged 12-19 years experienced the most dramatic rise, with ANA prevalence tripling (300% increase) from approximately 5% to 15% over the study period. This finding is particularly alarming because it suggests that younger generations face substantially higher autoimmune risk than their predecessors, with potential implications for lifelong disease burden. Males showed a 52% relative increase in ANA prevalence, non-Hispanic Whites experienced a 49% increase, and adults aged 50 and older saw a 68% increase—all statistically significant trends. Individual autoimmune diseases show similar patterns: type 1 diabetes prevalence has nearly doubled in 40 years, celiac disease has increased five-fold in 30 years doubling approximately every 15 years, multiple sclerosis cases worldwide rose 30% from 2013-2022, and inflammatory bowel disease increased 46% from 2006-2021. The autoimmune disease statistics in the US 2026 demonstrate that these increases are occurring globally, with worldwide incidence and prevalence rising 19.1% and 12.5% per year respectively, suggesting common environmental or lifestyle factors driving autoimmune disease development across diverse populations.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE